Apheresis Market Share & Trends [2033]

Apheresis Market Overview

The Apheresis Market size was valued at USD 1678.05 million in 2024 and is expected to reach USD 2543.84 million by 2033, growing at a CAGR of 4.4% from 2025 to 2033.

The apheresis market is experiencing significant growth due to the increasing prevalence of chronic diseases and advancements in medical technologies. In 2024, the global apheresis market was valued at approximately USD 3.1 billion, with projections indicating a rise to USD 5.6 billion by 2033. This growth is driven by the rising demand for blood components and the increasing adoption of apheresis procedures in therapeutic applications. North America holds a substantial share of the market, accounting for 39.77% in 2024, valued at USD 1,268.61 million.

The United States contributes significantly to this share, with a 71.09% stake. Asia-Pacific is emerging as a rapidly growing region, projected to reach USD 1,398.9 million by 2030. The market is segmented by product into devices, disposables & reagents, and software, with devices leading the segment. By method, centrifugation and membrane filtration are the primary techniques employed, catering to various applications such as renal diseases, neurology, cancer, hematology, and autoimmune diseases. The increasing incidence of blood-related disorders and the growing need for plasma-derived medicines are further propelling the market forward.

Key Findings

Driver: The primary driver of the apheresis market is the increasing prevalence of chronic diseases, including renal and autoimmune disorders, necessitating advanced therapeutic interventions.

Top Country/Region: North America leads the apheresis market, with the United States accounting for a significant 71.09% share within the region.

Top Segment: The devices segment dominates the market, driven by technological advancements and the rising adoption of automated apheresis systems in clinical settings.

Apheresis Market Trends

The apheresis market is witnessing several notable trends that are shaping its growth trajectory. One significant trend is the increasing adoption of apheresis procedures in the treatment of neurological disorders. For instance, therapeutic plasma exchange has become a standard treatment for conditions like Guillain-Barré syndrome and myasthenia gravis. The rising incidence of these disorders is contributing to the growing demand for apheresis procedures. Another trend is the technological advancement in apheresis devices. Modern apheresis machines are becoming more efficient, user-friendly, and capable of performing multiple procedures. These advancements are reducing procedure times and improving patient outcomes, thereby encouraging more healthcare facilities to adopt apheresis technologies. The market is also experiencing a shift towards the use of disposable apheresis kits. These kits offer advantages such as reduced risk of cross-contamination and ease of use, making them increasingly popular in clinical settings.

The disposables segment holds a significant share of the market, driven by the recurrent need for these products in every apheresis procedure. Furthermore, there is a growing emphasis on personalized medicine, which is influencing the apheresis market. Apheresis procedures are being tailored to individual patient needs, particularly in the collection of specific blood components for targeted therapies. This personalized approach is enhancing the efficacy of treatments and is expected to drive further adoption of apheresis technologies. Geographically, Asia-Pacific is emerging as a significant market for apheresis, with countries like China and India witnessing increased adoption of these procedures. Factors such as improving healthcare infrastructure, rising awareness about blood disorders, and increasing healthcare expenditure are contributing to this growth. The Asia-Pacific apheresis equipment market is projected to reach USD 1,398.9 million by 2030.

Apheresis Market Dynamics

DRIVER

Rising demand for pharmaceuticals.

The escalating demand for pharmaceuticals, particularly plasma-derived medicines, is a significant driver of the apheresis market. Apheresis procedures are essential in collecting plasma, which is a critical component in the production of various therapeutic products. The increasing prevalence of chronic diseases and the need for effective treatments are fueling the demand for these pharmaceuticals. Consequently, the need for efficient and reliable apheresis procedures is on the rise, propelling the market forward.

RESTRAINT

Demand for refurbished equipment.

The growing demand for cost-effective solutions in healthcare settings has led to an increased preference for refurbished apheresis equipment. While this trend helps in reducing capital expenditure, it poses a restraint to the market for new apheresis devices. The availability of refurbished equipment at lower prices can deter healthcare facilities from investing in new, technologically advanced devices, potentially hindering market growth.

OPPORTUNITY

Growth in personalized medicines.

The shift towards personalized medicine presents a significant opportunity for the apheresis market. Apheresis procedures can be customized to collect specific blood components tailored to individual patient needs, enhancing the efficacy of treatments. This personalized approach is gaining traction in various therapeutic areas, including oncology and autoimmune diseases, thereby opening new avenues for market expansion.

CHALLENGE

Rising costs and expenditures.

The high costs associated with apheresis procedures, including equipment, disposables, and maintenance, pose a challenge to market growth. These expenses can be a burden for healthcare facilities, especially in developing regions with limited budgets. Additionally, the need for trained personnel to operate apheresis machines adds to the operational costs, potentially limiting the adoption of these procedures.

Apheresis Market Segmentation

The apheresis market is segmented based on type and application. By type, it includes centrifugation and membrane filtration methods. By application, it encompasses renal diseases, neurology, cancer, hematology, and autoimmune diseases. Each segment contributes uniquely to the market's growth, driven by specific clinical needs and technological advancements.

By Type

Centrifugation: This method is widely used in apheresis procedures due to its efficiency in separating blood components based on density. Centrifugation-based apheresis devices are prevalent in clinical settings, offering rapid and reliable results. The demand for these devices is driven by their versatility and effectiveness in various therapeutic applications.
Membrane Filtration: is gaining popularity as a gentler alternative to centrifugation. This method uses semi-permeable membranes to separate plasma from blood cells, reducing the risk of cell damage. Membrane-based apheresis is particularly beneficial for patients requiring frequent procedures, as it minimizes adverse effects and enhances patient comfort.

By Application

Renal Diseases: Apheresis plays a crucial role in managing renal diseases by removing harmful substances from the blood. It is particularly effective in treating conditions like focal segmental glomerulosclerosis and Goodpasture's syndrome. The increasing incidence of kidney-related disorders is driving the demand for apheresis procedures in nephrology.
Neurology: apheresis is employed to treat autoimmune neurological disorders such as multiple sclerosis and myasthenia gravis. Therapeutic plasma exchange helps in removing pathogenic antibodies, providing symptomatic relief and improving patient outcomes. The rising prevalence of neurological conditions is contributing to the growth of this application segment.
Cancer: Apheresis is utilized in oncology for collecting peripheral blood stem cells for transplantation and for reducing high white blood cell counts in leukemia patients. These procedures are integral to cancer treatment protocols, enhancing the efficacy of therapies and patient survival rates.
Hematology: apheresis is used to manage various blood disorders by removing or collecting specific blood components. Conditions such as sickle cell anemia and polycythemia vera benefit from apheresis treatments, which help in alleviating symptoms and preventing complications.
Autoimmune Diseases: Apheresis is effective in treating autoimmune diseases by eliminating circulating autoantibodies and immune complexes. This approach is beneficial in conditions like systemic lupus erythematosus and rheumatoid arthritis, where conventional therapies may be insufficient. The growing incidence of autoimmune disorders is fueling the demand for apheresis procedures in this segment.

Apheresis Market Regional Outlook

The global apheresis market demonstrates strong regional diversity, with distinct growth trajectories influenced by healthcare infrastructure, regulatory frameworks, disease prevalence, and technological advancement. Each region exhibits unique adoption patterns and investment levels in apheresis technologies, contributing to varied market maturity and expansion prospects.

North America

remains the dominant region in the apheresis market, accounting for 39.77% of the global share in 2024. The United States alone is responsible for 71.09% of this regional contribution. Factors such as well-established healthcare systems, high awareness levels, and a growing incidence of chronic diseases like leukemia and autoimmune conditions are driving market penetration. The U.S. has more than 2,700 registered blood banks and transfusion centers utilizing apheresis equipment. Additionally, increased use of apheresis in stem cell collection and the rise of therapeutic plasma exchange procedures contribute to growing demand. In Canada, the apheresis market is expanding with the integration of plasma donation centers and mobile collection units across provinces, registering a 19% increase in therapeutic use cases between 2022 and 2024.

Europe

holds a significant share of the apheresis market due to its advanced medical technologies and increasing demand for plasma-derived therapies. Germany leads the regional market, accounting for more than 24% of the European share in 2024, followed by France and the UK. The presence of robust biopharmaceutical industries and government-funded research programs is boosting technological integration. The number of therapeutic apheresis procedures performed annually across Europe crossed 580,000 in 2023. In Germany alone, over 160 medical facilities now offer specialized therapeutic apheresis services. The European Medicines Agency (EMA) has also supported regulatory pathways for apheresis-based treatment approaches, increasing the speed to market for novel technologies.

Asia-Pacific

is the fastest-growing region in the apheresis market, expected to surpass USD 1,398.9 million by 2030 in valuation terms. China, India, and Japan are the key contributors. China alone accounted for over 250,000 apheresis procedures in 2023, with more than 1,200 registered apheresis centers. India's market is rapidly developing, supported by government-led plasma donation awareness programs, especially under the National Blood Transfusion Council. Japan has integrated apheresis in clinical practice for neurological diseases such as Guillain-Barré Syndrome and multiple sclerosis, reporting a 14.5% annual growth in therapeutic apheresis cases from 2022 to 2024. The rising prevalence of hematologic conditions and expanding access to advanced care are central to regional expansion.

Middle East & Africa

apheresis market is growing steadily, though it remains comparatively underdeveloped. The region is benefiting from increased investment in healthcare infrastructure, particularly in the Gulf Cooperation Council (GCC) countries. Saudi Arabia and the UAE are leading adopters, with a combined total of over 180 apheresis machines installed in major hospitals as of 2024. In Africa, South Africa leads the market with the highest volume of therapeutic plasma exchange treatments, registering a 12.3% increase in 2023. However, the broader region faces challenges such as lack of skilled personnel, low awareness, and limited access to advanced medical devices, slowing overall adoption.

List of Top Apheresis Companies

Asahi Kasei Medical
Terumo Corporation
Haemonetics Corporation
Fresenius Kabi
Cerus Corporation
Braun Melsungen
Kawasumi Laboratories
NIKKISO
Therakos
Medica S.p.A

Top Two Companies with the Highest Share

Haemonetics Corporation: holds the leading position globally with a share of over 18.6% in 2024. Its comprehensive portfolio, including the PCS2 and NexSys PCS plasma collection systems, is used in more than 60 countries. The company reported a 15% year-on-year growth in apheresis device sales due to increased adoption in both blood centers and therapeutic settings.

Terumo Corporation: ranks second, capturing approximately 14.2% of the market in 2024. Its Spectra Optia Apheresis System is widely used in hospitals for therapeutic plasma exchange, red cell exchange, and mononuclear cell collection. In Japan alone, Terumo recorded over 97,000 uses of Spectra Optia in 2023, with expanding adoption in Southeast Asia and Europe.

Investment Analysis and Opportunities

The apheresis market is attracting strong investment interest globally, primarily driven by the rising demand for blood components and advanced treatment solutions for chronic and autoimmune diseases. From 2022 to 2024, more than USD 2.7 billion was invested in apheresis-related technologies and infrastructure across North America, Asia-Pacific, and Europe. Private equity firms and venture capitalists are actively funding startups developing next-generation apheresis systems with AI-based automation and point-of-care capabilities. In 2023, a U.S.-based startup secured USD 68 million in Series C funding to launch a portable apheresis system suitable for remote clinics and military applications. Similarly, in India, a leading medical device firm invested USD 21 million to scale domestic production of plasma collection equipment. Pharmaceutical companies are also investing in expanding their apheresis capabilities for cell and gene therapy trials. In 2024, over 140 active clinical trials globally included apheresis as part of the treatment or sample collection protocol. A significant portion of these trials focuses on immunotherapies, where patient-derived cells are collected via apheresis.

Hospital groups and blood centers are expanding their apheresis infrastructure. In Germany, the number of therapeutic apheresis centers increased by 11% in 2023, fueled by government subsidies. China’s healthcare modernization program allocated over CNY 2.4 billion towards blood safety and plasma collection centers, boosting opportunities for international and local device manufacturers. Emerging markets are a hotbed for investment, particularly in sub-Saharan Africa and Southeast Asia, where healthcare access and infrastructure are improving. Equipment donations, public-private partnerships, and capacity-building programs are being prioritized to ensure these regions are better equipped for plasma-based treatments. The World Health Organization (WHO) also initiated a collaborative program with multiple countries to expand voluntary plasma donation, indirectly stimulating demand for automated collection systems. Overall, the global investment landscape for apheresis is shaped by strategic acquisitions, funding for innovation, and expansion into untapped markets. Companies that focus on automation, disposable kits, cost-efficiency, and training services are positioned to capture new opportunities.

New Product Development

Innovations in the apheresis market are accelerating rapidly, with manufacturers introducing more efficient, user-friendly, and technologically advanced systems. These developments are focused on reducing procedure time, improving patient outcomes, and enhancing usability for healthcare professionals. In 2023, Haemonetics launched the NexSys PCS® plasma collection system with Persona® technology, which allows personalized donation parameters. This system reportedly reduces collection time by 20% and increases plasma yield by 12%. Over 800 NexSys systems have been deployed in North America alone. Terumo BCT introduced enhancements to its Spectra Optia platform, integrating new software for more precise mononuclear cell collection and improved data tracking. The company recorded a 17% rise in system upgrades in Europe between 2022 and 2024. The Spectra Optia system is now being used for advanced therapies including CAR-T and stem cell transplants in over 30 countries. Fresenius Kabi developed a new therapeutic apheresis system with integrated AI support, allowing real-time monitoring of vital signs and automatic adjustment of flow rates. Initial trials in German hospitals indicated a 25% reduction in operator error and enhanced treatment safety.

Cerus Corporation is working on pathogen-reduction compatible apheresis platforms for emerging viral infections. In 2024, the company launched a clinical pilot across Southeast Asia in collaboration with public hospitals to test its Intercept® apheresis system. Disposable kits have also seen innovation, with companies introducing single-use, eco-friendly sets that reduce contamination risks and procedural downtime. These kits are particularly valuable in high-throughput donation centers. Asahi Kasei launched a new filtration membrane in 2023 that enhances plasma separation efficiency by 18% and is now deployed across 400 hospitals in Asia. Mobile apheresis units are being developed to serve remote or disaster-affected areas. In 2023, an Australian firm introduced a fully functional apheresis vehicle capable of performing up to 20 procedures per day, targeting rural areas and national emergencies. The push for innovation is not limited to hardware. New digital tools, such as procedure simulation software and cloud-based data monitoring, are also being integrated into apheresis solutions. These tools help ensure quality assurance, training, and better long-term patient management.

Five Recent Developments

Haemonetics Corporation deployed over 800 NexSys PCS systems across U.S. donation centers, improving plasma yield by 12% and reducing procedure time by 20%.
Terumo BCT upgraded its Spectra Optia systems with new software, resulting in a 17% increase in procedural accuracy and expanded use in CAR-T therapy trials.
Fresenius Kabi launched a new therapeutic apheresis device with built-in AI for vital monitoring, showing a 25% error reduction in clinical pilot studies.
Cerus Corporation initiated pathogen-reduction apheresis pilots in Southeast Asia, testing the Intercept® platform in 10 regional hospitals.
Asahi Kasei Medical introduced an 18% more efficient plasma filtration membrane, now operational in more than 400 Asian medical centers.

Report Coverage of Apheresis Market

This comprehensive report covers the global apheresis market in its entirety, offering in-depth analysis on key segments, technological advancements, and regional dynamics. It includes qualitative and quantitative insights into both donor and therapeutic apheresis, with focus on procedure volumes, device adoption, regulatory frameworks, and innovation pipelines. The report provides detailed segmentation by type (centrifugation, membrane filtration), application (neurology, hematology, renal diseases, autoimmune diseases, cancer), and geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa). Each segment is evaluated using factual metrics such as the number of installed devices, annual procedure counts, and adoption trends. Furthermore, the report explores competitive landscape metrics such as market shares, product portfolios, patent activity, and recent strategic moves.

It highlights emerging companies and technologies, while also analyzing investment trends across regions and sectors. Special emphasis is placed on innovation, including new product development, AI integration, and digital transformation within apheresis procedures. Also covered are the major regulatory and operational challenges facing the market—such as skilled labor shortages, high costs, and ethical considerations. The report evaluates both market restraints and potential growth opportunities, including the expansion of plasma-based therapeutics, rising demand for cell and gene therapy, and adoption in emerging healthcare markets. The data-driven methodology includes the use of procedure statistics, device installation rates, trial data, and investment tracking, ensuring a comprehensive and actionable outlook for stakeholders across the medical device, biotechnology, and healthcare service industries.